PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy

Prostate

Volumn 69, Issue 16, 2009, Pages 1802-1807

  Nelius, T ^a   Filleur, S ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen independent prostate cancer; Castration refractory prostate cancer; Chemotherapy; Docetaxel; Hormone refractory prostate cancer; Prostate cancer; PSA flare; PSA surge

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; DATA BASE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETREATMENT; TAXOIDS;

EID: 70350464485     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21024     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics. CA Cancer J Clin 2008;58(2):71-96.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ.A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419-424. (Pubitemid 19211484)
3. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or withoutflutamide for metastatic prostate cancer.NEngl J Med 1998;339(15):1036-1042.
4. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics. CA Cancer J Clin 2004; 54(1):8-29.
5. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506-2513. (Pubitemid 29368252)
6. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756-1764. (Pubitemid 26185452)
7. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer:A meta-analysis of individual patient data. Lancet Oncol 2007;8(11):994-1000. (Pubitemid 47629887)
8. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15):1513-1520.
9. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512. (Pubitemid 39315317)
10. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C,OhW, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-3467. (Pubitemid 29517916)
11. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005; 23(25):6139-6148. (Pubitemid 46300232)
12. Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16(5):1835-1843. (Pubitemid 28234729)
13. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23(15):3343-3351. (Pubitemid 46243478)
14. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007;13(5):1488-1492. (Pubitemid 46450439)
15. Fossa SD, Vaage S, Letocha H, Iversen J, Risberg T, Johannessen DC, Paus E, Smedsrud T. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)-delayed response and flare phenomenon should be considered. Scand J Urol Nephrol 2002;36(1):34-39. (Pubitemid 34225300)
16. Heidenreich A, Sommer F, Ohlmann CH, Schrader AJ, Olbert P, Goecke J, Engelmann UH. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 2004;101(5): 948-956. (Pubitemid 39100427)
17. Nelius T, Klatte T, de RieseW, Filleur S. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. Int Urol Nephrol 2008;40(1):97-104.
18. Olbert PJ, Hegele A, Kraeuter P, Heidenreich A, Hofmann R, Schrader AJ. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 2006;17(8):993-996. (Pubitemid 44350619)
19. Sella A, Sternberg CN, Skoneczna I, Kovel S. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int 2008;102(11):1607-1609.
20. Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K. The postchemotherapy PSA surge syndrome. Ann Oncol 2008; 19(7):1308-1311.
21. Mahler C. Is disease flare a problem? Cancer 1993;72(12 Suppl): 3799-3802.
22. Noguchi K, Uemura H, Harada M, Miura T, Moriyama M, Fukuoka H, Kitami K, Hosaka M. Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LHRH agonist. Int J Clin Oncol/Jpn Soc Clin Oncol 2001;6(1):29-33. (Pubitemid 32230360)
23. Sugiono M, Winkler MH, Okeke AA, Benney M, Gillatt DA. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer-A pilot study. Prostate Cancer Prostatic Dis 2005;8(1):91-94.
24. Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 2006;106(1):63-67. (Pubitemid 43032549)
25. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142(4):1011-1017. (Pubitemid 19250754)
26. Killian CS, Yang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, Slack NH, Papsidero LD, Murphy GP, Chu TM. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985;45(2):886-891. (Pubitemid 15161096)
27. Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000;163(4):1085-1089. (Pubitemid 30169367)
28. Leibovici D, Zisman A, Lindner A, Stav K, Siegel YI. PSA elevation during prostate cryosurgery and subsequent decline. Urol Oncol 2005;23(1):8-11. (Pubitemid 40692260)
29. de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 1998;78(10):1350- 1355.
30. Horwich A, Peckham MJ. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 1986;70(11):1329-1331. (Pubitemid 17184300)
31. Sonoo H, Kurebayashi J. Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 1996;26(4):250-257. (Pubitemid 26125852)
32. Sorbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol (Stockholm, Sweden) 2004;43(5):495-498. (Pubitemid 39037099)
33. Bork E, Hansen M, Urdal P, Paus E, Holst JJ, Schifter S, Fenger M, Engbaek F. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide. Eur J Cancer Clin Oncol 1988;24(6): 1033-1038. (Pubitemid 18141187)
34. Fischbach W, Schwarz-Wallrauch C, Jany B. Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer. Cancer 1989; 63(6):1143-1149. (Pubitemid 19074745)
35. Fizazi K, Cojean I, Pignon JP, Rixe O, Gatineau M, Hadef S, Arriagada R, Baldeyrou P, Comoy E, Le Chevalier T. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: An early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 1998;82(6):1049-1055.
36. Liu AY, True LD, LaTray L, Ellis WJ, Vessella RL, Lange PH, Higano CS, Hood L, van den Engh G. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 1999;40(3): 192-199. (Pubitemid 29334867)
37. van der Poel HG, Oosterhof GO, Schaafsma HE, Debruyne FM, Schalken JA. Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 1997;49(4):652-657. (Pubitemid 27161435)
38. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7): 1148-1159.